Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients
Authors:
- Liv LorenzLLLiv Lorenz
- Melissa WeissnerMWMelissa Weissner
- Helen UllrichHUHelen Ullrich
- Alberto PolimeniAPAlberto Polimeni
- Thomas MuenzelTMThomas Muenzel
- Tommaso GoriTommaso Gori
- 1 October 2018
- journal article
- research article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 14 (9) , e1011-e1019
Abstract
Aims: The safety of bioresorbable scaffolds (BRS) has recently been challenged. However, it is unclear whether outcomes depend on the complexity of the lesion or on the technique used to implant the device. The aim of this study was to report on the outcomes after BRS implantation in complex lesions. Methods and results: This investigator-initiated, single-centre, single-arm observational study recruited 657 consecutive patients (79% male, 66.7% acute coronary syndrome, age 63 +/- 12 years). Three hundred and twenty-two lesions (42.3%) in 297 (45.2%) patients with type B2 or C lesions were classified as the "complex lesions group". Post-procedural residual stenosis was slightly but significantly greater in the complex lesions group (15.7 +/- 11.3% vs. 13.5 +/- 10.2%, p=0.0109). The median follow-up was 1,076 (762-1,206) days without difference between groups. The Kaplan-Meier rates of early scaffold thrombosis (3.5% vs. 1.1%, p=0.0478, HR 3.03 [1.06-8.70]) and scaffold restenosis (9.9% vs. 9.1%, p=0.0262, HR 2.34 [1.11-4.94]) were higher in patients with complex lesions than in those with simple lesions. Late/very late thrombosis, death, repeat myocardial infarction, or repeat coronary interventions were not different. In patients in whom strict guidelines for implantation were applied, the incidence of thrombosis was reduced by 76% in complex lesions and by 92% in simple ones, such that there were no differences between groups (2.3% vs. 0.5%, p=0.3899). In contrast, the incidence of scaffold restenosis was reduced by 59% and 89%, and a difference between groups persisted (7.0% vs. 1.6%, p=0.0235). Conclusions: BRS implantation in complex lesions is, as expected, associated with higher incidence of events as compared to simple ones. The technique used at the time of the implantation, however, reduces the incidence of adverse outcomes.Keywords
This publication has 20 references indexed in Scilit:
- Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended RegistryEuroIntervention, 2017
- Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusionsEuroIntervention, 2017
- Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary LesionsJACC: Cardiovascular Interventions, 2017
- Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total OcclusionsCirculation: Cardiovascular Interventions, 2017
- Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registryEuroIntervention, 2016
- Bioresorbable Scaffolds for the Management of Coronary Bifurcation LesionsJACC: Cardiovascular Interventions, 2016
- Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategyCatheterization and Cardiovascular Interventions, 2015
- 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular ScaffoldsJACC: Cardiovascular Interventions, 2014
- Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes MellitusJACC, 2014
- Late Stent Recoil of the Bioabsorbable Everolimus-Eluting Coronary Stent and its Relationship With Plaque MorphologyJACC, 2008